Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre

Clinical Drug Investigation

Volumn 30, Issue SUPPL. 1, 2010, Pages 27-31

  Stimolo, Clementina ^a   Del Favero, Valentina ^a   Zecchinato, Giancarlo ^a   Buson, Roberto ^a   Cusin, Davide ^a   Pellachin, Patrizia ^a   Simonetto, Pamela ^a  

^a UOC Dipendenze SerD Este   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; COCAINE; DIAMORPHINE; METHADONE; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; COCAINE DEPENDENCE; CONSTIPATION; DRUG MISUSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HEROIN DEPENDENCE; HUMAN; INSOMNIA; ITALY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; REHABILITATION CENTER; TOXICOLOGY; TREATMENT DURATION; ADDICTION; DIAGNOSIS; DRUG COMBINATION; DRUG DEPENDENCE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; OPIOID-RELATED DISORDERS; PREVENTION AND CONTROL; PSYCHOLOGY; SUBLINGUAL DRUG ADMINISTRATION; SUBSTANCE ABUSE; SUBSTANCE WITHDRAWAL SYNDROME; TIME; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; ANALGESICS, OPIOID; BEHAVIOR, ADDICTIVE; BUPRENORPHINE; DRUG COMBINATIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; ITALY; MALE; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT SATISFACTION; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952361233     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11536030-000000000-00000     Document Type: Article

References (16)

1. Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs 2006; 20 (9): 697-712.
2. Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009; 69 (5): 577-607.
3. Jenkinson RA, Clark NC, Fry CL, et al. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005 Feb; 100 (2): 197-205.
4. Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among French drug users. Addiction 2001 Feb; 96 (2): 267-272.
5. Sakol MS, Stark C, Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow-an increase. Br J Addict 1989 Apr; 84 (4): 439-441.
6. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003 May 21; 70 (2 Suppl.): S59-77.
7. Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000 Dec 22; 61 (1): 85-94.
8. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007 Apr 17; 88 (1): 75-78.
9. Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004; 13 Suppl. 1: S42-66.
10. Bell J, Byron G, Gibson A, et al. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev 2004 Sep; 23 (3): 311-317.
11. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl JMed 2003 Sep 4; 349 (10): 949-958.
12. Kamien JB, Branstetter SA, Amass L. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients. Heroin Addict Relat Clin Probl 2008; 10 (4): 5-18.
13. Stoller KB, Bigelow GE, Walsh SL, et al. Effects of buprenorphine/ naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001 Mar; 154 (3): 230-242.
14. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994 May; 55 (5): 569-580.
15. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000 Feb 1; 58 (1-2): 143-152.
16. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001 Jan 1; 61 (2): 173-181.